BioLamina

Brandi Halvorson

🇨🇳 China

8.9

Reviewed: July 3, 2024

• - Stability Studies
• - 18 months January 2023 - June 2024
• - Pharmaceutical Company

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Stuart Osinski

🇮🇹 Italy

5.7

Reviewed: June 10, 2024

• - Project Management
• - 12 weeks March - May 2024
• - Biotech Company

Communication from the project management team was poor, with frequent missed deadlines. This caused significant frustration on our end, as we had to repeatedly chase them for updates. The project eventually got back on track, but the delays were problematic.

Stanley Waters Jr.

🇮🇳 India

8.7

Reviewed: May 22, 2023

• - Patient Recruitment
• - 8 weeks March - April 2023
• - Clinical Research Organization

The patient recruitment strategies were highly effective, and the project was completed within the agreed timeframe. The team was very professional, and their expertise in patient engagement was evident throughout.

Raquel Gutmann MD

🇨🇳 China

9.1

Reviewed: September 5, 2024

• - Pharmacovigilance Services
• - Ongoing
• - Pharmaceutical Company

The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.

Alton Hahn

🇮🇹 Italy

9.5

Reviewed: April 10, 2023

• - Gene Therapy Development
• - 12 weeks January - March 2023
• - Research Institution

The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.

Dr. Emmett Rohan

🇯🇵 Japan

6

Reviewed: September 12, 2024

• - Health Technology Assessment
• - 8 weeks July - September 2024
• - Pharmaceutical Company

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.

Luz Davis

🇲🇽 Mexico

5.8

Reviewed: April 5, 2024

• - Biostatistical Design
• - 6 weeks February - March 2024
• - Research Institution

The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.

Francis Toy

🇬🇧 United Kingdom

9.2

Reviewed: February 15, 2023

• - Data Analysis
• - 4 weeks January 2023
• - Pharmaceutical Company

The team provided exceptional data analysis services, and the project was completed well within the timeline. Communication was clear and consistent, which made the whole process smooth. Highly recommended for anyone needing reliable clinical data management.

Mercedes Morissette

🇸🇦 Saudi Arabia

9

Reviewed: June 18, 2023

• - Clinical Protocol Design
• - 6 weeks April - May 2023
• - Pharmaceutical Company

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Brett Monahan

🇨🇳 China

5.4

Reviewed: October 3, 2024

• - Process Development
• - 14 weeks June - September 2024
• - Biotech Company

The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.